In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.
The NAM, NAS, and Royal Society have formed a commission to develop a framework on the proper use of genome editing, and convened its first meeting in Washington, DC, this week.
Novartis replaced two top executives from its AveXis unit following data manipulation during early testing of its new gene therapy, Reuters reports.
A new study finds that a positive lab environment can encourage undergraduates to continue to perform research.
ScienceInsider reports that researchers funded through the Cancer Moonshot program will have to make their papers immediately accessible to the public.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
The firms announced a deal to develop services and products for sequencing-based T cell and B cell receptor profiling in the US and Europe.
Researchers in California link additional genes to autism risk, HealthDay News reports.
Through the NeuroGAP-Psychosis program, researchers hope to include more individuals of African ancestry in genetic research, as they write at WBUR.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.